Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06624189 | Active Choice Clinical Decision Support (CDS): Hepatocellular Carcinoma (HCC) Screening in Patients With Cirrhosis | enrolling by invitation | — | 1,300 | NYU Langone HealthOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06789848 | Ligufalimab and Cadonilimab in Advanced Liver Cancers | recruiting | Phase 2 | 64 | University of Texas Southwestern Medical CenterOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07432347 | Decoding Epigenetic Mechanisms Driving Immune Evasion in Liver Cancer With Omics Approaches(DELIVER) | recruiting | — | 270 | Niguarda HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07436845 | Impact of Emotional Status on Prognosis of Patients With BCLC Stage B/C Hepatocellular Carcinoma Undergoing Hepatic Arterial Infusion Chemotherapy Combined With Targeted and Immunotherapy | recruiting | — | 90 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437859 | Exploring the Application of 3D Bioprinting for Personalized Treatment in Primary Liver Cancer With Tumor Microenvironment | active not recruiting | — | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT05441475 | A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients | enrolling by invitation | Phase 2 | 118 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Feb 25, 2026 | clinicaltrials |
| NCT04134559 | Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma | recruiting | Phase 2 | 18 | Allison O'Neill, MDOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT05438420 | Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 120 | Qurient Co., Ltd.INDUSTRY | 2 | Feb 24, 2026 | clinicaltrials |
| NCT07429864 | Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide(Bio-Delta) | recruiting | — | 20 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT07428356 | Histotripsy for Ablation of Liver Tumours in Asia(HALT) | recruiting | N/A | 40 | National Cancer Centre, SingaporeOTHER | 1 | Feb 23, 2026 | clinicaltrials |
| NCT05488522 | SBRT With Atezo/Bev for HCC | recruiting | Phase 1 | 18 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT05096715 | Atezolizumab+Bevacizumab+SBRT in Unresectable HCC | recruiting | Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07417397 | Adjuvant TACE in HCC With High-risk Recurrence Factors | recruiting | Phase 3 | 442 | Guangxi Medical UniversityOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT07148050 | Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells(IMPACT) | recruiting | Phase 1 | 21 | Seattle Children's HospitalOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07412054 | Lenvatinib and Pembrolizumab With or Without BCAA in Unresectable HCC(BLP-HCC) | not yet recruiting | Phase 2 | 234 | Fudan UniversityOTHER | 0 | Feb 17, 2026 | clinicaltrials |
| NCT07414433 | Validation of Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma(BLOOD-TACE-M) | not yet recruiting | — | 60 | University of BelgradeOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07408804 | Comparison of Response Between Combination of Transarterial Chemoembolization and Lenvatinib Therapy Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma | recruiting | N/A | 40 | Bangladesh Medical UniversityOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT07410715 | Surgery vs. Watch-and-Wait Strategy in Complete Responders for Hepatocellular Carcinoma (SWITCH)(SWITCH) | not yet recruiting | — | 100 | West China HospitalOTHER | 0 | Feb 13, 2026 | clinicaltrials |
| NCT06027086 | DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC) | recruiting | Phase 1 / Phase 2 | 27 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT07392866 | A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 2 / Phase 3 | 120 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07395635 | Phase II Trial of Immunonutrition in Hepatectomy | recruiting | N/A | 100 | Tata Memorial CentreOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT05375370 | Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA(REMNANT) | recruiting | N/A | 150 | University Hospital, RouenOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT07391839 | MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma. | recruiting | Phase 1 | 40 | Suzhou Mednovo Yi Medical Technology Co., Ltd.OTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07365930 | NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy(NISTIPS) | recruiting | — | 350 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07378709 | Exploratory Blood-Based Biomarkers in TACE-Treated Hepatocellular Carcinoma(BLOOD-TACE-P) | recruiting | — | 15 | University of BelgradeOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06061328 | Project OASIS: Optimizing Approaches to Select Implementation Strategies(OASIS) | enrolling by invitation | N/A | 8,020 | VA Office of Research and DevelopmentFED | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04736121 | Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients(DOORwaY90) | active not recruiting | N/A | 100 | Sirtex MedicalINDUSTRY | 1 | Feb 3, 2026 | clinicaltrials |
| NCT06904170 | Durvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Chemotherapy in Hepatocellular Carcinoma(ALICE) | recruiting | Phase 2 / Phase 3 | 196 | UNICANCEROTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07178587 | Evaluating the roLe of Multiplexed PET Imaging in the Detection and Staging of hepatocellulaR Carcinoma and gAstro-entero-pancreatic Tumors(ELMIRA) | recruiting | N/A | 28 | Nantes University HospitalOTHER | 1 | Feb 3, 2026 | clinicaltrials |
| NCT07380633 | Toripalimab Plus Bevacizumab Combined Three Intra-arterial Therapies (TACE, HAIC, or TACE-HAIC) for Unresectable Hepatocellular Carcinoma: a Phase 2, Multicenter Randomised Non-comparative Trial | active not recruiting | Phase 2 | 90 | Sun Yat-sen UniversityOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT07312162 | Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots | recruiting | — | 730 | University of Southern CaliforniaOTHER | 1 | Jan 30, 2026 | clinicaltrials |
| NCT01918683 | TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients | active not recruiting | N/A | 40 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05113186 | Neoadjuvant and Adjuvant Lenvatinib in HCC Patients Treated by Percutaneous Ablative(LENVABLA) | active not recruiting | Phase 2 | 32 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT07174570 | Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer | recruiting | Phase 2 | 39 | Emory UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT02081755 | Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer | enrolling by invitation | Phase 4 | 336 | Baylor Research InstituteOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07369505 | Sapu003 in Advanced mTOR-sensitive Solid Tumors | recruiting | Phase 1 | 27 | SAPU NANO (US) LLCINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT07368023 | A Retrospective Study of Safety and Efficacy of Locoregional Therapies Combined With Anti-VEGF/TKIs and Immune Checkpoint Inhibitors for All Comers of Intention-to-treat Patients With Unresectable Hepatocellular Carcinoma | not yet recruiting | — | 300 | Ningbo Medical Center Lihuili HospitalOTHER_GOV | 1 | Jan 26, 2026 | clinicaltrials |
| NCT07368049 | MR 7700 Multinuclear Application Clinical Study | not yet recruiting | N/A | 100 | Philips Clinical & Medical Affairs GlobalINDUSTRY | 0 | Jan 26, 2026 | clinicaltrials |
| NCT07348211 | First in Human Study of SIM0610 in Solid Tumors(SIM0610-101) | recruiting | Phase 1 | 260 | Jiangsu Simcere Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07363512 | Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus | not yet recruiting | Phase 2 | 27 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 23, 2026 | clinicaltrials |
| NCT07364357 | A Phase I Study of CREPT-618 in Locally Advanced HCC | recruiting | Phase 1 | 13 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 23, 2026 | clinicaltrials |
| NCT07039201 | A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC) | recruiting | N/A | 12 | Zhejiang UniversityOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT07358975 | Prediction of Complications in Hepatic Tumors | not yet recruiting | Phase 4 | 192 | Rigshospitalet, DenmarkOTHER | 1 | Jan 22, 2026 | clinicaltrials |
| NCT03539822 | Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies(CAMILLA) | recruiting | Phase 1 / Phase 2 | 117 | Anwaar SaeedOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05155189 | A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma | recruiting | Phase 1 | 72 | Zhejiang UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05198609 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | active not recruiting | Phase 3 | 214 | Sun Yat-sen UniversityOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT07356037 | Nanocrystalline Megestrol Acetate for Cachectic Stage Locally Advanced Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 68 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT05366829 | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | recruiting | Phase 2 | 35 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 27, 2026source: clinicaltrials